A case of a medullary thyroid carcinoma developing in the course of ulcerative colitis

Yıl 2011, Cilt: 10 Sayı: 2, - , 01.08.2011

Mesut Sezikli Züleyha Akkan Çetinkaya Fatih Güzelbulut Meryem Günay Gürleyik Atakan Yeşil Selvinaz Özkara Hayrünnisa Sezikli Ayşe Oya Kurdaş Övünç

Öz

Thyroid carcinoma accounts for 1% of all malignancies, and medullary thyroid carcinoma accounts for 5-10% of the thyroid carcinomas. It can be sporadic or familial. The sporadic forms are especially diagnosed late in the course of the disease. Thyroid carcinoma usually presents with symptoms and signs related to local invasion to adjacent structures and hormone secretion, such as flushing and diarrhea. Extraintestinal manifestations are well-known clinical features of ulcerative colitis. They develop prior to or during the course of the disease. Medullary thyroid carcinoma has not been reported in patients with ulcerative colitis to date, and only one case of papillary thyroid carcinoma has been reported. Because medullary thyroid carcinoma can present with diarrhea, it is difficult to make a diagnosis in patients with ulcerative colitis, which also manifests with diarrhea. Therefore, all diarrheal attacks should not be attributed to ulcerative colitis in these patients; instead, other possibilities should be evaluated. We report a case of medullary thyroid carcinoma developing in the course of ulcerative colitis.

Anahtar Kelimeler

Medullary thyroid carcinoma, diarrhea, ulcerative colitis

Ülseratif kolit takibinde tiroid medüller karsinoma gelişen bir vaka, olgu sunumu

Öz

Tiroid karsinomu tüm kanserler içinde %1 oranında görülürken medüller tiroid karsinomu, tiroid kanserlerinin yaklaşık %5-10'unu oluşturur. Sporadik ya da ailevi olabilir. Özellikle sporadik formlar daha geç tanı almaktadır. Klinik semptomlar genellikle lokal invazyon ve hormon sekresyonuna bağlı ciltte kızarma ve diyare gibi semptomlardır. Ekstraintestinal bulgular ülseratif kolitin iyi bilinen klinik özelliklerindendir. Bunlar tanı öncesi veya klinik seyir sırasında ortaya çıkabilir. Literatürde medüller tiroid karsinomu ile ülseratif kolit birlikteliği şimdiye kadar gösterilmemiş olup sadece papiller tiroid kanseri ile eşlik eden bir olgu sunumu vardır. Ayrıca medüller tiroid karsinoması'nın ishal şikayeti ile beraber gitmesi, ülseratif kolit kliniği nedeni ile hastaya tanısal yaklaşımı zorlaştırmaktadır. Ülseratif kolit tanısı mevcut hastalarımızda her ishal atağını mevcut tanıya bağlamayıp diğer nedenler de dışlanmalıdır. Bu yazıda ülseratif kolit seyrinde gelişen bir medüller karsinomu vakasını sunduk.

Anahtar Kelimeler

Medüller tiroid karsinoma, ishal, ülseratif kolit

Kaynakça

• Ünal G, Çerçel A. Medüller tiroid kanseri. In: Tiroid hastalıkları. G. Ünal. Cerrahpaşa Tıp Fakültesi Yayınları: İstanbul. 2000; 422-35.
• Sadler GP, Clark OH, Heerden JA. Thyroid and parathyroid. In: Schwartz SI, Principles of Surgery. 7thEd. New York, McGraw-Hill, 1999; 1661-715.
• Cohen R, Quidville V, Bihan H. Medullary thyroid carcinoma and hormones. Ann Med Interne (Paris) 2003; 154: 109-16.
• Cohen R, Campos JM, Salaün C, et al. Preoperative calcitonin levels are predictive of tumor size and post operative calcitonin normali- zation in medullary thyroid carcinoma. Groupe d'Etudes des Tume- urs a Calcitonine (GETC). J Clin Endocrinol Metab 2000; 85: 919- 22.
• Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol 2011; 23: 22-7.
• Evgenikos N, Stephen JG. Papillary thyroid carcinoma associated with ulcerative colitis. Postgrad Med J 1996; 72: 621-2.
• Marcén R, Galeano C, Fernández-Rodriguez A, et al. Effects of the new immunosuppressive agents on the occurrence of malignanci- es after renal transplantation. Transplant Proc 2010; 42: 3055-7.
• Gawlik T, d'Amico A, Szpak-Ulczok S, et al. The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report. Thyroid Res 2010; 3: 10.
• Conzo G, Ruggiero R, Palazzo A, et al. The RET gene and medul- lary thyroid cancer: from mutations to the planning of therapy. Chir Ital 2009; 61: 531-8.
• Weber T, Schilling T, Franck-Rau K, et al. Impact of modified radi- cal neck dissection on biochemical cure in medullary thyroid carci- nomas. Surgery 2001; 130: 1044-9.
• Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocri- ne neoplasia type 2A. Ann Surg 1994; 220: 237-47.
• Jaggard MK, MacRae C, Ifeacho S, et al. New presentation of fa- milial medullary thyroid carcinoma in 87-year-old patient with high- risk RET proto-oncogene codon 620 mutation. J Laryngol Otol 2009; 123: 796-800.
• Pinchot SN, Kunnimalaiyaan M, Sippel RS, Chen H. Medullary thyroid carcinoma: targeted therapies and future directions. J On- col 2009; 2009: 183031.
• Dackiw AP. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010; 43: 365-74, ix.
• Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lympho- mas in transplantation patients. Transplant Proc 1969; 1: 106-12.
• Ginsberg GG, Goodman ZD, Lewis JH. A 22-year-old man with thyroid cancer and cholestatic liver disease. Semin Liver Dis 1991; 11: 64-71.